ALK inhibitor - J Ints Bio
Alternative Names: Anaplastic lymphoma kinase inhibitor - J Ints BioLatest Information Update: 28 Jun 2024
At a glance
- Originator Joseah Biopharma
- Developer J Ints Bio
- Class Antineoplastics
- Mechanism of Action Anaplastic lymphoma kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in South Korea
- 29 May 2020 Preclinical trials in Non-small cell lung cancer in South Korea (unspecified route), before May 2020 (Joseah Biopharma pipeline, May 2020)